Wednesday, February 24, 2021
Home Business Compugen is expanding its collaboration agreement with Bristol Myers Squeeze

Compugen is expanding its collaboration agreement with Bristol Myers Squeeze


Compugen, which develops drugs for cancer immunotherapy, today announced the expansion of its clinical collaboration agreement with Bristol Myers Squeeze. Under the terms of the extended agreement, Bristol Myers Skove will provide Opdivo, a PD-1 immune control protein inhibitor, for the Phase 1b clinical trial expansion phase of COM701, a first-of-its-kind antibody to compression against PVRIG, in combination with Opdivo in certain cancers. Article link https://www.news1.news/news/2021/02/compugen-is-expanding-its-collaboration-agreement-with-bristol-myers-squeeze.html

The trial is expected to begin in the second quarter of 2021.

Dr. Anat Cohen-Daig, President and CEO of CompuGen: “We are excited to expand our clinical program to evaluate COM701, a first-of-its-kind antibody against PVRIG. While our current trial, which combines the three immune control protein inhibitors, COM701 with inhibitors Bristol Myers Scooby’s PD-1 and TIGIT provide the ultimate test of our scientific hypothesis, our studies suggest that some patients may not need triple therapy and may be satisfied with a combination of only two drugs.With completing the recruitment of patients to the COM701 dosing arm combined with Opdivo , And evidence of early signs of anticancer activity, we are prepared to further examine the effect of combining these two drugs by expanding the experiment.Examining the activity of COM701 in three treatment modalities – as a single treatment, in combination with PD-1 inhibitor and in combination with PD-1 inhibitors and -TIGIT, may provide additional insights into the contribution of the various treatment components as well as an opportunity to expand treatment options with the COM701 to meet the needs of different patients.We are proud to move rapidly towards the start of this trial, based on previous biological markers and data, which we believe have Article link https://www.news1.news/news/2021/02/compugen-is-expanding-its-collaboration-agreement-with-bristol-myers-squeeze.html

- Advertisement -

The probability e “It is extremely important to respond to the combined blockade of PVRIG and PD-1, which will strengthen us as leaders in the field of treatments that focus on the biological axis DNAM.”

Under the terms of the agreement, Bristol Myers Squeeve will continue to provide Opdivo for a trial run by CompuGen. Article link https://www.news1.news/news/2021/02/compugen-is-expanding-its-collaboration-agreement-with-bristol-myers-squeeze.html

The Phase 1b clinical trial, which is part of Compuigen’s COM701 clinical trial as a monotherapy and as part of a combination therapy (NCT03667716), will examine regular doses of COM701 and Opdivo, based on the results of the Phase 1a clinical trial to evaluate increasing doses of this combination. Based on the company’s research analyzes and an initial anti-cancer response observed at the appointment stage, in the extended part of the trial, patients with ovarian cancer, breast cancer, and MSS will be recruited.

As part of its clinical collaboration with Bristol Myers Squeeve, COM701 has also been tested as a triple therapy in combination with Opdivo and BMS-986207, a Bristol Myers Squeeve antibody being developed against TIGIT.




Important Alert

Dear reader.
I hope you are in health and well.
I offer you important instructions regarding this article

  • We only want readers to access information quickly and easily using other multilingual content, rather than information only available in a specific language.
  • We always respect the copyright of the author's content and always include
    the original link of the Source Article , and if the author does not agree, leave the report below the article, the article will be edited or deleted at the author's request. Thank you so much! Warm greetings!


.

Source link
https://www.sponser.co.il/Article.aspx?ArticleId=103884


LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments